Do Analysts Expect Ascendis Pharma A/S (ASND) Stock to Rise After It Is Lower By -15.50% in a Month?

Analysts who follow Ascendis Pharma A/S (ASND) on average expect it to rise 74.86% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 63, which means it ranks higher than 63 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating ASND a Strong Buy today. Find out what this means to you and get the rest of the rankings on ASND!

See Full ASND Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Ascendis Pharma A/S Stock Today?

Ascendis Pharma A/S (ASND) stock is higher by 1.61% while the S&P 500 is down -1.64% as of 2:07 PM on Friday, May 20. ASND has risen $1.47 from the previous closing price of $91.13 on volume of 240,252 shares. Over the past year the S&P 500 is lower by -7.75% while ASND is down -32.64%. ASND lost -$8.52 per share the over the last 12 months. Click Here to get the full Stock Report for Ascendis Pharma A/S stock.